...
首页> 外文期刊>Clinical and laboratory haematology >BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
【24h】

BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).

机译:250例墨西哥慢性粒细胞白血病(CML)患者中的BCR / ABL p210,p190和p230融合基因。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

There are two major forms of the BCR/ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcripts b2a2 or b3a2 code for a p210 protein. Another fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 protein. Another, less common fusion gene is c3a2[e19a2], which encodes a p230 protein. The incidence of one or the other rearrangement in chronic myeloid leukaemia (CML) patients varies in different reported series. This study was designed to determine the frequency of coexpresion of the p210, p190 and p230 transcripts in 250 Mexican patients with CML. We performed nested and multiplex reverse transcriptase polymerase chain reaction (RT-PCR) on bone marrow samples from adult patients and found that all cases were positive for some type of BCR/ABL rearrangement. In 226 (90.4%) patients it was p210, while the remaining 9.6% showed coexpression or one of the transcripts of p190/p210/p230. In 7% of patients with p210 expression there are both isoforms (b3a2/b2a2), presumably the result of alternative splicing. The rate of coexpression of the p190/p210 transcripts was 5%, which is much lower than in other reports. This may be due to the technical factors. These patients had high platelet counts, marked splenomegaly and chromosomal abnormalities in addition to Ph'. Other types of coexpression seen were p210/p230 and p190/p210/p230, in patients with high-risk clinical factors. Our study confirms the occurrence of coexpression of different BCR/ABL transcripts, although the rate (9.6%) was much lower than has been reported in other populations. This may reflect either the sensitivity of the detection techniques used or the possibility of genetic differences between the populations studied. Coexpression may be due to alternative splicing or to phenotypic variation, with clinical courses different from classical CML.
机译:BCR / ABL融合基因有两种主要形式,涉及ABL外显子2,但包括BCR基因的不同外显子。转录本b2a2或b3a2编码p210蛋白。另一个融合基因导致表达e1a2转录本,该转录本编码p190蛋白。另一个不太常见的融合基因是c3a2 [e19a2],它编码p230蛋白。慢性粒细胞白血病(CML)患者中一种或另一种重排的发生率在不同的报道系列中有所不同。本研究旨在确定250例墨西哥CML患者中p210,p190和p230转录本的共表达频率。我们对成年患者的骨髓样本进行了嵌套和多重逆转录聚合酶链反应(RT-PCR),发现所有病例对于某些类型的BCR / ABL重排均呈阳性。在226名(90.4%)患者中为p210,其余9.6%显示共表达或p190 / p210 / p230的转录本之一。在7%的p210表达患者中,有两种亚型(b3a2 / b2a2),可能是替代剪接的结果。 p190 / p210转录本的共表达率为5%,远低于其他报道。这可能是由于技术因素造成的。这些患者除Ph'外,还有高血小板计数,明显的脾肿大和染色体异常。在具有高风险临床因素的患者中观察到的其他类型的共表达是p210 / p230和p190 / p210 / p230。我们的研究证实了不同BCR / ABL转录本共表达的发生,尽管其发生率(9.6%)远低于其他人群。这可能反映了所用检测技术的敏感性或所研究人群之间遗传差异的可能性。共表达可能是由于选择性剪接或表型变异所致,其临床过程不同于经典CML。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号